Subtype
Thyroid Gland Anaplastic Carcinoma
CI-CAN-00004121ATCExplore in graph →
22 active trials2 approved drugs5 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004121ATCExplore in graph →
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | active not recruiting | Phase 1 | 98 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL) | recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER |
| 1 |
| Sep 8, 2026 |
| clinicaltrials |
| NCT07485569 | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial(REPOTHYROID-II) | active not recruiting | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | recruiting | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04420754 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | active not recruiting | Phase 1 | 70 | AffyImmune Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials